-
1 in 3 Americans will have diabetes by 2050 Some will respond to drug treatment and some will not. Better therapeutic outcomes can be achieved with applied clinical genetics.
Learn More -
Semantically linked clinical and pharmacogenomic data Advanced analytics powered by semantically linked clinical and pharmacogenomic data.
Learn More -
Careers at PanGenX Work with us to impove disease treatment outcomes with advanced clinical genetics and technology innovation.
Careers
Diabetes Clinical Decision Support
Our initial solution is focused on the Type II Diabetes (T2D) pandemic. Our pharmacogenomic knowledge base captures clinical evidence for how genetic variations in patients affect their response to existing and emerging T2D drugs.
This knowledge is the foundation for the modeling, analytics and visualization capabilities that reduce the time and expense traditionally associated with delivering safe, efficacious treatments to T2D patients.
The PanGenX Difference
We offer advanced analytics powered by semantically linked pharmacogenomic and clinical data for innovative drug development and personalized therapy. This approach combined with carefully curated clinical knowledge for each therapeutic segment, leads our customers to better-informed clinical decisions.